MCID: PLS009
MIFTS: 51

Plasma Cell Neoplasm

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Plasma Cell Neoplasm

MalaCards integrated aliases for Plasma Cell Neoplasm:

Name: Plasma Cell Neoplasm 12 15 73
Plasma Cell Dyscrasia 12 73
Paraproteinemias 44 73
Plasma Cell Tumour 12
Plasmacytic Tumor 12
Multiple Myeloma 73
Plasmacytoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:6536
MeSH 44 D010265
SNOMED-CT 68 277576009 71390001

Summaries for Plasma Cell Neoplasm

MalaCards based summary : Plasma Cell Neoplasm, also known as plasma cell dyscrasia, is related to monoclonal paraproteinemia and extramedullary plasmacytoma. An important gene associated with Plasma Cell Neoplasm is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and B cell receptor signaling pathway (KEGG). The drugs Vidarabine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Plasma Cell Neoplasm

Diseases related to Plasma Cell Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 monoclonal paraproteinemia 34.4 CD40LG CD79A
2 extramedullary plasmacytoma 30.9 B2M IL6 MYOM2
3 heavy chain disease 30.8 CD40LG CD79A
4 peripheral nervous system disease 30.3 CD40LG MAG MYOM2
5 plasmacytoma 29.5 B2M CD38 CD79A IL6 MYC PTPRC
6 myeloma, multiple 25.7 B2M CD19 CD38 CD40LG CD79A IL6
7 refractory plasma cell neoplasm 12.1
8 necrobiotic xanthogranuloma 11.3
9 selective igg deficiency disease 11.0 CD40LG CD79A
10 c1q nephropathy 11.0 CD40LG CD79A
11 meningovascular neurosyphilis 11.0 CD40LG CD79A
12 alpha chain disease 11.0 CD40LG CD79A
13 brill-zinsser disease 11.0 CD40LG CD79A
14 exudative glomerulonephritis 11.0 CD40LG CD79A
15 cork-handlers' disease 11.0 CD40LG CD79A
16 salpingo-oophoritis 10.9 CD40LG CD79A
17 early yaws 10.9 CD40LG CD79A
18 ventilation pneumonitis 10.9 CD40LG CD79A
19 chronic interstitial cystitis 10.9 CD40LG CD79A
20 axillary adenitis 10.9 CD40LG CD79A
21 cryofibrinogenemia 10.9 CD40LG CD79A
22 trichostrongyloidiasis 10.9 CD40LG CD79A
23 subacute bacterial endocarditis 10.9 CD40LG CD79A
24 heterophyiasis 10.9 CD40LG CD79A
25 immunoglobulin g deficiency 10.9 CD40LG CD79A
26 orbital granuloma 10.9 CD40LG CD79A
27 hyperglobulinemic purpura 10.9 CD40LG CD79A
28 gastroduodenitis 10.9 CD40LG CD79A
29 bacterial conjunctivitis 10.9 CD40LG CD79A
30 ophthalmia neonatorum 10.9 CD40LG CD79A
31 immunoglobulin a deficiency 1 10.9 CD40LG CD79A
32 indolent myeloma 10.9 B2M MYOM2
33 parotid disease 10.9 CD40LG CD79A
34 cerebral arteritis 10.9 CD40LG CD79A
35 encapsulated thymoma 10.9 CD38 CD79A
36 selective immunoglobulin deficiency disease 10.9 CD40LG CD79A
37 smoldering myeloma 10.9 CD79A MYOM2
38 geniculate herpes zoster 10.8 CD40LG CD79A
39 erythema elevatum diutinum 10.8 CD40LG CD79A
40 sclerosing keratitis 10.8 B2M CD79A
41 sporotrichosis 10.8 CD40LG CD79A
42 fallopian tube disease 10.8 CD40LG CD79A
43 hyperimmunoglobulin syndrome 10.8 CD40LG CD79A
44 congenital syphilis 10.8 CD40LG CD79A
45 salpingitis 10.8 CD40LG CD79A
46 ocular toxoplasmosis 10.8 CD40LG CD79A
47 dysgammaglobulinemia 10.8 CD40LG CD79A
48 acute maxillary sinusitis 10.8 CD40LG CD79A
49 spinocerebellar ataxia, autosomal recessive 10 10.7 CD40LG CD79A
50 autoimmune disease of central nervous system 10.7 CD40LG MAG

Comorbidity relations with Plasma Cell Neoplasm via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Bronchitis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Monoclonal Paraproteinemia
Neutropenia Osteoporosis

Graphical network of the top 20 diseases related to Plasma Cell Neoplasm:



Diseases related to Plasma Cell Neoplasm

Symptoms & Phenotypes for Plasma Cell Neoplasm

GenomeRNAi Phenotypes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CD79A MAG MYC NCAM1 NUP214 PTPRC

MGI Mouse Phenotypes related to Plasma Cell Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 CD38 NCAM1 CD40LG NUP214 CD79A IL6
2 hematopoietic system MP:0005397 10.06 CD40LG CD79A PCSK5 IL6 B2M MAEA
3 immune system MP:0005387 10 CD40LG CD79A PCSK5 IL6 B2M MAEA
4 digestive/alimentary MP:0005381 9.91 NSD2 IL6 B2M CD19 MYC PCSK5
5 mortality/aging MP:0010768 9.9 MYC NCAM1 CD40LG NSD2 NUP214 IL6
6 neoplasm MP:0002006 9.43 MYC CD79A IL6 B2M CD19 PTPRC
7 nervous system MP:0003631 9.32 NCAM1 CD40LG CD79A IL6 B2M CD19

Drugs & Therapeutics for Plasma Cell Neoplasm

Drugs for Plasma Cell Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 692)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
3
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
4
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
5
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
6
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
7
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
10
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
11
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
12
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
13
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
14
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
16
Phentolamine Approved Phase 4 50-60-2 5775
17
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
18
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
19 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
20
Liraglutide Approved Phase 4 204656-20-2 44147092
21
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
22
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
23
Pirarubicin Investigational Phase 4 72496-41-4
24
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
25 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
26 Epoetin alfa Phase 4,Phase 3,Phase 2,Not Applicable 113427-24-0
27 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Hematinics Phase 4,Phase 3,Phase 2,Not Applicable
34 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Hypoglycemic Agents Phase 4,Phase 1,Phase 2
45 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 2515)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
2 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
3 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
4 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
5 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
6 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
7 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
8 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
9 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
10 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
12 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
13 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
15 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
16 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
17 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
18 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
19 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
20 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
21 An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
22 PDD vs PAD to Treat Initially Diagnosed MM Recruiting NCT02577783 Phase 4 Chemotherapy with PDD regimen;Chemotherapy with PAD regimen
23 Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Active, not recruiting NCT01087008 Phase 4 zoledronic acid
24 Modified Bortezomib-based Combination Therapy for Multiple Myeloma Active, not recruiting NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
25 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Enrolling by invitation NCT02958969 Phase 4 Apixaban;Placebo Oral Tablet
26 Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients. Not yet recruiting NCT02006225 Phase 4 Plerixafor
27 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Not yet recruiting NCT02920190 Phase 4 Liraglutide
28 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
29 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
30 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
31 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
32 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
33 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
34 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
35 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
36 High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
37 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
38 CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
39 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. Unknown status NCT01908621 Phase 3 G-CSF (filgrastim);Cytosine arabinoside + G-CSF (filgrastim)
40 Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
41 A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma Unknown status NCT01470131 Phase 3 masitinib 6 mg/kg/day;placebo
42 CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
43 MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation Unknown status NCT00256776 Phase 3 Velcade (Bortezomib);Thalidomide;Dexamethasone
44 Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Unknown status NCT02066454 Phase 3 Apixaban
45 Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Unknown status NCT00998270 Phase 2, Phase 3
46 Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy Unknown status NCT00571168 Phase 3 Emend;Placebo
47 VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) Unknown status NCT01134484 Phase 3 Velcade;Thalidomide;Dexamethasone
48 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
49 Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years Unknown status NCT01532856 Phase 3 Thalidomide, Cyclophosphamide, Dexamethasone;Thalidomide, Dexamethasone;Thalidomide, Melphalan, Prednisone
50 Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone

Search NIH Clinical Center for Plasma Cell Neoplasm

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: paraproteinemias

Genetic Tests for Plasma Cell Neoplasm

Anatomical Context for Plasma Cell Neoplasm

MalaCards organs/tissues related to Plasma Cell Neoplasm:

41
Bone, Bone Marrow, T Cells, B Cells, Kidney, Testes, Myeloid

Publications for Plasma Cell Neoplasm

Articles related to Plasma Cell Neoplasm:

(show top 50) (show all 59)
# Title Authors Year
1
Thymic plasma cell neoplasm infiltration in SjAPgren's syndrome with monoclonal gammopathy. ( 29590476 )
2018
2
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. ( 29403080 )
2018
3
Crystal-Storing Histiocytosis with Plasma Cell Neoplasm in the Setting of Chronic Carbamazepine Exposure. ( 29874901 )
2018
4
Corrigendum to "Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship?" [Urology Case Reports 6 (2017) 50-52]. ( 29541578 )
2017
5
Plasma cell neoplasm as a risk factor for early thrombosis of arteriovenous fistula. ( 28762615 )
2017
6
Aberrant CD3 Expression in a Relapsed Plasma Cell Neoplasm. ( 29268594 )
2017
7
Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia. ( 28057674 )
2017
8
Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship? ( 27175345 )
2016
9
Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling. ( 26955130 )
2016
10
Cytology of plasma cell rich effusion in cases of plasma cell neoplasm. ( 27756988 )
2016
11
Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study. ( 26796980 )
2016
12
Dual CD3 and CD4 positive plasma cell neoplasm with indistinct morphology: a diagnostic pitfall. ( 27133529 )
2016
13
Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains. ( 26339430 )
2015
14
Osseous plasma cell neoplasm of the mandible for initial diagnosis of multiple myeloma: case report and literature review. ( 25861199 )
2015
15
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. ( 25851555 )
2015
16
Nodal involvement of extranodal marginal zone lymphoma with extreme plasmacytic differentiation (Mott cell formation) simulating plasma cell neoplasm and lymphoplasmacytic lymphoma. ( 25548763 )
2014
17
Practical diagnostic approaches to composite plasma cell neoplasm and low grade B-cell lymphoma/clonal infiltrates in the bone marrow. ( 24395190 )
2014
18
Image of the month : a rare presentation of a plasma cell neoplasm. ( 25333092 )
2014
19
Epstein-Barr virus-driven bone marrow aplasia and plasmacytosis mimicking a plasma cell neoplasm. ( 24405048 )
2014
20
Crystal-storing histiocytosis with IgD I_-associated plasma cell neoplasm. ( 25028748 )
2014
21
Classical Hodgkin lymphoma with coexistant plasma cell neoplasm: A case report. ( 25308039 )
2014
22
Intracellular and extracellular immunoglobulin crystals assuming a multitude of geometric shapes in an IgG-I> plasma cell neoplasm. ( 23720061 )
2013
23
Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. ( 23814762 )
2013
24
Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. ( 23792270 )
2013
25
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2013
26
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. ( 22774220 )
2012
27
CD3 expression in plasma cell neoplasm (multiple myeloma): a diagnostic pitfall. ( 23172088 )
2012
28
Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. ( 22658896 )
2012
29
Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. ( 22429092 )
2012
30
Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. ( 21851219 )
2011
31
Plasma cell neoplasm in conjunction with glioblastoma of the conus medullaris. ( 21325257 )
2011
32
A quantitative analysis of genomic instability in lymphoid and plasma cell neoplasms based on the PIG-A gene. ( 20060400 )
2010
33
Mandibular radiolucency. Plasma cell neoplasm. ( 19906620 )
2009
34
Ophthalmic presentation of plasma cell neoplasm. ( 19617795 )
2009
35
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. ( 17363561 )
2007
36
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. ( 16759389 )
2006
37
Myc translocations in B cell and plasma cell neoplasms. ( 16815105 )
2006
38
Clinical implication of centrosome amplification in plasma cell neoplasm. ( 16373658 )
2006
39
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. ( 15735016 )
2005
40
Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQAr): Patient Version ( 26389437 )
2002
41
Peripheral neuropathy associated with experimental plasma cell neoplasm in the mouse. ( 3029337 )
1987
42
Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. ( 3917376 )
1985
43
Thyroid-gland plasma cell neoplasm (plasmacytoma). ( 7027992 )
1981
44
Plasma cell neoplasm involving the thyroid. ( 638958 )
1978
45
An unusual case of a plasma cell neoplasm with an IgG3lambda myeloma and a gamma3 heavy chain disease protein. ( 412532 )
1978
46
Tumor cell invasion of hepatocytes in transplantable plasma cell neoplasm of mice. ( 4344454 )
1972
47
Ploidy fluctuations of mouse plasma-cell neoplasm MSPC-1 during serial transplantation. ( 5157581 )
1971
48
Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine. ( 4254308 )
1970
49
Studies on the murine plasma-cell neoplasm, X5563. II. Accelerated immunologic reactivity to transplanted tumor induced in C3H mice by transferred immune rabbit cells. ( 6053557 )
1967
50
PLASMA CELL NEOPLASM ARISING IN A CAF MOUSE. CHARACTERISTICS AND RESPONSE TO CERTAIN CHEMOTHERAPEUTIC AGENTS. ( 14207853 )
1964

Variations for Plasma Cell Neoplasm

Copy number variations for Plasma Cell Neoplasm from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17396 1 142600000 155000000 Gain Plasma-cell dyscrasia

Expression for Plasma Cell Neoplasm

Search GEO for disease gene expression data for Plasma Cell Neoplasm.

Pathways for Plasma Cell Neoplasm

GO Terms for Plasma Cell Neoplasm

Cellular components related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 B2M CD38 CD40LG NCAM1 PTPRC
2 external side of plasma membrane GO:0009897 9.1 B2M CD19 CD40LG CD79A NCAM1 PTPRC

Biological processes related to Plasma Cell Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.72 CD38 CD40LG IL6 MAEA MYC
2 negative regulation of neuron projection development GO:0010977 9.43 B2M CD38 MAG
3 negative regulation of bone resorption GO:0045779 9.37 CD38 IL6
4 positive regulation of T cell proliferation GO:0042102 9.33 CD40LG IL6 PTPRC
5 B cell proliferation GO:0042100 9.13 CD40LG CD79A PTPRC
6 B cell receptor signaling pathway GO:0050853 8.92 CD19 CD38 CD79A PTPRC

Sources for Plasma Cell Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....